Insulin degludec and liraglutide: adverse event reports filed with FDA

1,197

reports as suspect product

0% of all reports · about 125 a year

141

reports, 12 months to June 2026

163 in the 12 months before

72.9%

marked serious by the reporter

28% across the class

5%

record death among outcomes, as reported

60 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Insulin degludec and liraglutide reports recording the termmedian drug in glp-1 receptor agonist

1. Blood glucose increasedraised blood sugar reading14.3%171
2. Nauseafeeling sick8.5%102
3. Vomitingbeing sick5.7%68
4. Diarrhoealoose or frequent stools5.3%64
5. Hypoglycaemialow blood sugar5.1%61
6. Glycosylated haemoglobin increaseda raised HbA1c, the long-term sugar measure3.9%47
7. Acute kidney injurysudden loss of kidney function3.8%45
8. Decreased appetitereduced appetite3.7%44
9. Dizzinesslight-headedness or unsteadiness3.3%40
10. Hyperglycaemiahigh blood sugar3.2%38
11. Hospitalisationadmission to hospital3%36
12. Blood glucose decreasedlow blood sugar reading2.9%35
13. Weight decreasedweight loss2.8%34
14. Lactic acidosisa build-up of lactic acid in the blood2.8%33
15. Astheniaweakness or lack of energy2.3%27
16. Dehydrationdehydration2.2%26
17. Covid-19COVID-19 infection2.1%25
18. Device failurethe device failed1.8%22
19. Diabetes mellitus inadequate controldiabetes not well controlled1.8%22
20. Pancreatic carcinoma1.8%22
21. Headachehead pain1.7%20
22. Falla fall1.6%19
23. Abdominal painstomach or belly pain1.5%18
24. Constipationconstipation1.5%18
25. Off label useused for a purpose or in a way not on the label1.5%18
26. Hyperkalaemiahigh blood potassium1.3%16
27. Pancreatitisinflammation of the pancreas1.3%16
28. Urinary tract infectionbladder or urinary infection1.3%16
29. Abdominal distensiona bloated abdomen1.3%15
30. Condition aggravatedthe condition being treated got worse1.2%14

Top 30 of 245 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 18 drugs in the glp-1 receptor agonist class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 404,853 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 35.4% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 1,197 reports.

Drugs most often listed in the same reports

Other products listed in reports where Insulin degludec and liraglutide is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the glp-1 receptor agonist class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Insulin degludec and liraglutide as a suspect or interacting product; reports listing it only as a concomitant medication (431) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.